NXTC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.9M
-54.2%
15.1M
+49.4%
10.1M
+3.6%
9.8M
+9.1%
8.9M
R&D
4.5M
-38.9%
7.4M
+8.6%
6.8M
+0.5%
6.8M
+10.8%
6.1M
SG&A
4.4M
+70.8%
2.6M
-20.8%
3.3M
+10.6%
3.0M
+5.3%
2.8M
Operating Income
-6919000
+54.2%
-15094000
-49.4%
-10105000
-3.6%
-9757000
-9.1%
-8945000
EBITDA
-8963000
+8.0%
-9745000
+0.8%
-9822000
-4.6%
-9392000
-11.7%
-8412000
Net Income
-6846000
+54.0%
-14892000
-52.0%
-9796000
-3.8%
-9436000
-9.4%
-8624000
EPS (Basic)
$-1.29
+53.9%
$-2.80
-49.7%
$-1.87
+21.1%
$-2.37
+26.4%
$-3.22
EPS (Diluted)
$-1.29
+53.9%
$-2.80
-49.7%
$-1.87
+21.1%
$-2.37
+26.4%
$-3.22
Shares (Diluted)
5.3M
+0.0%
5.3M
+1.3%
5.2M
+31.5%
4.0M
+48.9%
2.7M
NextCure (NXTC) — Financials